Spontaneous/Natural menopause is the final menstrual period confirmed after 12 consecutive months of amenorrhea with no pathological cause.
Induced menopause is the permanent cessation of menstruation after bilateral oophorectomy (ie surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy).
Perimenopause/Menopause transition/Climacteric is the duration when menstrual cycle & endocrine changes occur a few years before and 12 months after the final menstrual period resulting from natural menopause.
Premature menopause is menopause before 40 years of age whether natural or induced while early menopause is spontaneous or induced menopause that occurs before the average age of natural menopause at 51 years or under 45 years of age.
The use of an oestradiol patch in addition to oral intermittent micronized progesterone for 1 year helped prevent the development of depressive symptoms in women going through menopause, particularly those in the early stages of the menopause transition, a recent study found.
New drug applications approved by US FDA as of 16 - 30 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Abaloparatide increases bone mineral density (BMD) at the ultradistal radius along with lower risk of wrist fracture compared with placebo and teriparatide in postmenopausal women with osteoporosis, according to a study presented at The Endocrine Society Annual Meeting (ENDO 2017) in Orlando, Florida, US.
A novel treatment targeting the neurokinin 3 receptor (NK3R) pathway with MLE4901, a NK3R antagonist, significantly reduces the frequency and severity of menopausal hot flushes, as well as the impact on daily life of menopausal women compared with placebo, according to a study presented at The Endocrine Society Annual Meeting (ENDO 2017) in Orlando, Florida, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Endocrinology - Malaysia digital copy today!
Patients with type 2 diabetes (T2D) and severe obesity may have a greater chance of complete T2D remission 1 year after gastric bypass rather than sleeve gastrectomy, according to results of the Oseberg* trial.
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
The transcultural Diabetes Nutrition Algorithm (tDNA) which involves a structured low-calorie meal plan, diabetes-specific meal replacements and enhanced physical activity, is effective for weight loss in patients with type 2 diabetes, a local study shows. [BMJ Open Diabetes Res Care 2017;5(1):e000384. Doi:10.1136/bmjdrc-2016-000384th]